All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Formation Bio, Jiangsu Chia Tai Feng Hai Pharmaceutical license autoimmune drug FHND5032, $500M milestones
Licensing deal, autoimmune, small molecule, milestone payments - Read more

Repertoire Immune Medicines, Eli Lilly collaborate on autoimmune tolerizing therapies, $85M upfront, $1.84B milestones
Research collaboration, autoimmune, T cell therapy, milestone payments - Read more

THE GOOD
Clinical Trials

CERo reports positive Ph1 safety data for CER-1236 chimeric engulfment receptor therapy in acute myeloid leukemia
Cell therapy, cancer, chimeric engulfment receptor T-cell therapy, acute myeloid leukemia, myelodysplastic syndrome - Read more

Ascletis reports positive Ph3 safety results for denifanstat (ASC40) FASN inhibitor targeting acne vulgaris
Small molecule, dermatological, FASN inhibitor, acne vulgaris, sebum production - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Company Launches

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development platform
Small molecule, oncology, strategic, major transaction - Read more

THE GOOD
Earnings & Finances

Takeda lifts guidance as Vyvanse decline narrows, prepares for new drug launches including oveporexton, rusfertide
Small molecule, neurological, financial, strategic, competitive - Read more

THE GOOD
Fundraises

Agomab Therapeutics aims for $212M IPO, immunology trials for Crohn's disease candidates
Cancer, clinical-stage, oncology, small molecule - Read more

Altimmune raises $75M registered direct offering for pemvidutide Phase 3 MASH trial
Liver disease, small molecule, clinical-stage, dual agonist - Read more

Vaxcyte raises $550M public offering, clinical-stage vaccine innovation company
Vaccine innovation, clinical-stage, infectious disease, platform technology - Read more

THE GOOD
Investments

AstraZeneca pledges $15B investment in China operations through 2030 for cell therapies and radioconjugates development
Cell therapy, oncology, strategic, major transaction - Read more

THE GOOD
Lawsuits

Novo Nordisk gets U.S. Chamber of Commerce support for Supreme Court challenge to IRA drug pricing provisions
GLP-1 agonist, diabetes, regulatory, financial - Read more

THE GOOD
Regulatory

FDA accepts Summit Therapeutics, Akeso's ivonescimab filing targeting PD-1/VEGF for EGFR-mutated non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1/VEGF targeting - Read more

THE GOOD
Strategic Plans

Sanofi CEO Hudson defends vaccine strategy amid declining sales, sees acquisition opportunities in uncertain market
Vaccines, infectious disease, strategic, financial - Read more

Roche wants to be in the “top three” in the obesity market with personalized weight-loss pipeline against Novo Nordisk, Eli Lilly
Obesity therapeutics, metabolic disorders, strategic, competitive - Read more

Sanofi allocates €15B ($17.87B) M&A budget to counter looming Dupixent patent cliff through strategic acquisitions
Immunology, neurology, rare disease, strategic, major transaction, financial - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Quince Therapeutics' eDSP (dexamethasone sodium phosphate) fails Ph3 trial for ataxia-telangiectasia treatment
Cell therapy, neurological, autologous erythrocyte encapsulation, ataxia-telangiectasia, dexamethasone - Read more

THE BAD
Earnings & Finances

Sanofi vaccine sales decline 2.5% in Q4, expects slightly negative growth in 2026 amid challenging environment
Vaccine, infectious disease, financial, operational - Read more

Roche's Vabysmo reports second consecutive quarter of declining sales, down 1% to $1.3B
Monoclonal antibody, ophthalmology, financial, revenue impact - Read more

THE BAD
Lawsuits

Public Citizen files FOIA lawsuit against HHS seeking disclosure of Trump's MFN pricing deals with Pfizer, Eli Lilly
Drug pricing policy, regulatory, strategic, transparency - Read more

THE BAD
Regulatory

FDA sends second untitled letter to ARS Pharmaceuticals criticizing Neffy epinephrine nasal spray TV advertisement
Nasal spray, allergic reactions, regulatory, operational - Read more

THE BAD
Strategic Plans

Sanofi scraps final RIPK1 inhibitor eclitasertib from disappointing Denali Therapeutics pact after phase 2 failures
Small molecule, autoimmune, strategic, major transaction - Read more

Roche drops Kiniksa Pharmaceuticals' vixarelimab targeting oncostatin M receptor beta from Ph2 idiopathic pulmonary fibrosis program
Antibody, fibrosis, monoclonal antibody, idiopathic pulmonary fibrosis, oncostatin M receptor beta, pipeline discontinuation - Read more

Sanofi abandons phase 1 mRNA seasonal flu vaccine program, shifts focus to high-dose vaccines
mRNA vaccine, infectious disease, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here